SPRYD5 Inhibitors
Chemical inhibitors of SPRYD5 can modulate its activity through various signaling pathways by targeting specific kinases and enzymes that are crucial for its function. Staurosporine, a broad-spectrum kinase inhibitor, can non-selectively inhibit a wide range of protein kinases that are potentially involved in the phosphorylation and regulation of SPRYD5, leading to a decrease in its activity. Similarly, Bisindolylmaleimide I and GF109203X, both of which are selective inhibitors of protein kinase C (PKC), can suppress SPRYD5 activity by inhibiting PKC-mediated signaling pathways that could otherwise phosphorylate and activate SPRYD5. LY294002 and Wortmannin, as phosphoinositide 3-kinases (PI3K) inhibitors, can disrupt the PI3K/AKT pathway, thereby potentially reducing SPRYD5's involvement in downstream signaling processes that rely on this pathway.
In addition to these, inhibition of the mitogen-activated protein kinase (MAPK) pathways can also affect SPRYD5 activity. U0126 and PD98059 are both MEK inhibitors that can prevent the activation of the extracellular signal-regulated kinase (ERK) pathway, which may play a role in the regulation of SPRYD5. In conjunction, SP600125 and SB203580 can inhibit the c-Jun N-terminal kinase (JNK) and p38 MAP kinase, respectively, which are also part of the MAPK signaling pathways. By impeding these kinases, these inhibitors can diminish SPRYD5's activity if it is modulated by JNK or p38 MAPK signaling. Furthermore, Rapamycin, which inhibits the mammalian target of rapamycin (mTOR), can lead to decreased activity of SPRYD5 if there is a functional linkage between SPRYD5 and the mTOR signaling pathway. Finally, Triciribine can specifically inhibit AKT phosphorylation and activation, which can suppress SPRYD5 if its function is dependent on AKT signaling. Go6983, another broad-spectrum PKC inhibitor, can further ensure the suppression of SPRYD5's activity by inhibiting various PKC isoforms, affirming the reduction of SPRYD5's role in cellular signaling.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. SPRYD5 is associated with kinase signaling pathways. By inhibiting kinases, Staurosporine could reduce phosphorylation events that are necessary for SPRYD5 activity, resulting in functional inhibition. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I selectively inhibits protein kinase C (PKC). As PKC is involved in signaling pathways that may regulate SPRYD5 function, its inhibition could lead to a decrease in SPRYD5 activity through reduced phosphorylation-dependent regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. PI3K is part of the AKT signaling pathway, which could interact with SPRYD5 function. Inhibition of PI3K could lead to reduced AKT activity, potentially decreasing SPRYD5's involvement in downstream signaling processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK, which is upstream of the ERK pathway. Since SPRYD5 may be influenced by ERK signaling, U0126 could inhibit the functional activity of SPRYD5 by preventing its regulation by the MEK/ERK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK signaling pathways. If SPRYD5's function is regulated by JNK signaling, SP600125 would inhibit this interaction, leading to a decrease in SPRYD5's functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. By inhibiting p38, which may be involved in the regulation of SPRYD5, SB203580 could impede the functional activity of SPRYD5 associated with p38 MAPK signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor, specifically blocking the activation of ERK. Inhibition of MEK/ERK signaling could lead to reduced functional activity of SPRYD5 if it is regulated by this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor, known to block AKT signaling. It could inhibit SPRYD5 function by reducing the AKT pathway's activity, which may be necessary for SPRYD5's role in cellular signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a central protein in regulating cell growth and proliferation. Inhibition of mTOR could lead to decreased SPRYD5 activity if SPRYD5 functions are linked to the mTOR signaling pathway. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits AKT phosphorylation and activation. If SPRYD5 activity is dependent on AKT signaling, triciribine would functionally inhibit SPRYD5 by blocking its AKT-mediated regulation. | ||||||